Meridian Medical Technologies, a Kindeva Drug Delivery Company, Investing $100+ Million in Bridgeton, Missouri, Expansion

Meridian Medical Technologies, a Kindeva Drug Delivery Company, a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced today, during National Community Development Week, it will expand manufacturing capabilities in Bridgeton, Missouri — investing more than $100 million over the next four years in a newly purchased facility. Meridian, which recently combined with Kindeva, will be converting this new 155,000-square-foot facility to support increased production of drug-device combination products, sterile fill-finish capabilities, and create job opportunities in the St. Louis area.

“We’re proud to have a leading, high-tech manufacturer like Meridian Medical Technologies expanding in St. Louis,” said Gov. Mike Parson. “It’s always exciting to see a local employer thriving, creating jobs, and developing innovative products right here in our state. We wish Meridian the best and look forward to its future growth as it continues to succeed in the region.”

Meridian founded the autoinjector technology and has been a leading manufacturer of emergency autoinjectors for more than 60 years. Now with Kindeva, the combined company has a broader range of drug delivery capabilities that this Bridgeton facility investment will help support worldwide.

“Meridian brings a strong history of specific expertise to support critical manufacturing capabilities for complex products — addressing a manufacturing shortage we have seen increase over the last several years,” said Milton Boyer, Meridian CEO. “Building a broader platform with the latest technologies and equipment available, coupled with enhanced capabilities in the production of pre-filled syringes and cartridges, will enable Meridian to offer a broader array of CDMO services and increased capacity to our customers.”

Since January 2022, Meridian has added approximately 300 employees for a total of approximately 900 in the St. Louis area. The company’s new facility, which will be completed in 2024, will support continued growth by dramatically increasing its abilities to develop and manufacture products that will bring new medicines to new markets and customers worldwide.

For this expansion, Meridian will benefit from the Missouri Works program, a tool that helps companies expand and retain workers by providing access to capital through withholdings or tax credits for job creation.

“It’s exciting to see Meridian Medical Technologies create more opportunities for Missourians in St. Louis,” said Maggie Kost, Acting Director of the Department of Economic Development. “As Meridian expands while developing lifesaving products, we’re grateful to support its growth. This company is another example of a quality local employer making a positive difference for our state and beyond.”

What Others Are Saying

“The city of Bridgeton welcomes Meridian Medical Technologies to the city,” said Mayor Terry Briggs. “Not only will Meridian bring well-paying jobs to our city, but the medical products it develops here will help countless people throughout the world. We look forward to working with them.”

“The expansion of Meridian Medical Technologies is a significant step forward for St. Louis,” said County Councilwoman Kelli Dunaway. “Their investment in our community not only brings economic benefits, but also underscores St. Louis’ position as a hub for innovation and advancement in the healthcare industry. It is exciting to see a company like Meridian recognize the potential in our region, and we look forward to the positive impact they will have on our community.”

“The expansion of Meridian Medical Technologies will provide more jobs and increase production in St. Louis County,” said County Executive Dr. Sam Page. “With the help of the St. Louis Economic Development Partnership, we have worked to create a path for growth to a business that employs approximately 900 people in St. Louis County.”

“Meridian’s expansion brings not only new investment and new jobs to the St. Louis metro, but highlights the continued growth of our bioscience and advanced manufacturing sectors,” said Jason Hall, CEO of Greater St. Louis, Inc. “We are excited by Meridian’s expansion and their commitment to St. Louis and appreciate the hard work and collaboration of the economic development partners at the state and regional level who helped make this project happen.”

“The St. Louis region has so much to offer in the biosciences and medical industry. We are excited Meridian Medical Technologies will be expanding its operations here and bringing more jobs to Missouri,” said Tara Oglesby, Vice President of Community, Economic Development and Energy Solutions at Ameren Missouri. “Ameren Missouri’s Smart Energy Plan continues to be instrumental in making the region more attractive for businesses to grow here while also providing reliable energy to power the quality of life for the customers and communities we serve.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”